ArticleLeukemia2022

A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.

Mohammed O Gbadamosi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.